We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 3

Figure 3. From: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Pedigree of a Lynch syndrome family with two MSH2 mutation carriers with urinary bladder cancer. CRC, colorectal cancer.

R S van der Post, et al. J Med Genet. 2010 July;47(7):464-470.
2.
Figure 2

Figure 2. From: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder (original magnifications, 400×) of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control.

R S van der Post, et al. J Med Genet. 2010 July;47(7):464-470.
3.
Figure 1

Figure 1. From: Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Absence of nuclear immunohistochemical staining of MLH1 protein (A) and presence of MSH2 protein (B) in urothelial carcinomas (UC) of the urinary bladder (original magnifications, 250×) of a patient carrying a germline MLH1 mutation. Note in figure 1A the presence of nuclear staining in normal mucosa and absence in carcinoma.

R S van der Post, et al. J Med Genet. 2010 July;47(7):464-470.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk